MCID: PLC008
MIFTS: 45

Placenta Disease

Categories: Fetal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Placenta Disease

MalaCards integrated aliases for Placenta Disease:

Name: Placenta Disease 11 14 16
Placenta Diseases 19 43 75
Pregnancy Complications 43 71
Placenta Disorder 19 75
Placenta Disorders 71

Classifications:



External Ids:

Disease Ontology 11 DOID:780
ICD9CM 34 646.9
ICD10 31 O43
UMLS 71 C0032045 C0032962 C0151864 more

Summaries for Placenta Disease

Disease Ontology: 11 A uterine disease that is located in the placenta.

MalaCards based summary: Placenta Disease, also known as placenta diseases, is related to placenta accreta and oligohydramnios, and has symptoms including morning sickness, hyperemesis gravidarum and late pregnancy bleeding. An important gene associated with Placenta Disease is PAPPA (Pappalysin 1), and among its related pathways/superpathways are Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) and Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors. The drugs Levoleucovorin and Remifentanil have been mentioned in the context of this disorder. Affiliated tissues include placenta, heart and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia: 75 A placental disease is any disease, disorder, or pathology of the... more...

Related Diseases for Placenta Disease

Diseases related to Placenta Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 472)
# Related Disease Score Top Affiliating Genes
1 placenta accreta 32.1 PGF PAPPA CGB3 AFP
2 oligohydramnios 32.1 PGF PAPPA MIR517A CGA AFP
3 placenta praevia 32.1 PGF PAPPA MIR525 MIR518D MIR517A
4 placental insufficiency 31.9 SERPINC1 PGF PAPPA MIR520A F3 CGA
5 pre-eclampsia 31.7 SERPINC1 PGF PAPPA MTHFR F5 F3
6 eclampsia 31.7 SERPINC1 PGF PAPPA MTHFR F3 APOH
7 placental abruption 31.7 SERPINC1 PGF PAPPA MTHFR MIR517A F5
8 gestational diabetes 31.7 PGF PAPPA MIR518D
9 thrombophilia 31.4 SERPINC1 MTHFR F5 F3 APOH ANXA5
10 pregnancy loss, recurrent 1 31.2 MTHFR F5 APOH
11 antiphospholipid syndrome 31.1 SERPINC1 PGF MTHFR F5 F3 APOH
12 thrombophilia due to thrombin defect 31.1 SERPINC1 MTHFR F5 F3 APOH
13 severe pre-eclampsia 31.0 SERPINC1 PGF PAPPA MIR520A MIR517A F5
14 ectopic pregnancy 30.8 PAPPA MIR525 MIR517A MIR371A CGB7 CGB5
15 hellp syndrome 30.8 SERPINC1 PGF MTHFR HADHA F5 F3
16 hyperhomocysteinemia 30.8 SERPINC1 MTHFR F5 APOH
17 hydatidiform mole, recurrent, 1 30.7 CGB5 CGB3 CGA
18 thrombophilia due to activated protein c resistance 30.7 SERPINC1 MTHFR F5 F3 APOH
19 pulmonary embolism 30.6 SERPINC1 MTHFR F5 F3 APOH
20 thrombocytopenia 30.6 SERPINC1 MTHFR F5 F3 APOH ANXA5
21 purpura 30.6 SERPINC1 F3 APOH
22 down syndrome 30.6 PGF PAPPA MTHFR CGB7 CGB5 CGB3
23 thrombotic thrombocytopenic purpura 30.5 SERPINC1 F3 APOH
24 protein s deficiency 30.5 SERPINC1 MTHFR F5 F3 APOH
25 twin-to-twin transfusion syndrome 30.5 PGF PAPPA
26 gestational trophoblastic neoplasm 30.5 PGF PAPPA MIR517A MIR371A CGB5 CGB3
27 hypertension, essential 30.5 SERPINC1 PGF PAPPA MTHFR MIR520A MIR518D
28 thrombosis 30.4 SERPINC1 MTHFR F5 F3 APOH ANXA5
29 chromosomal triplication 30.4 PAPPA CGB7 CGB3 AFP
30 stroke, ischemic 30.4 SERPINC1 MTHFR F5 F3 APOH ANXA5
31 vascular disease 30.4 SERPINC1 MTHFR F5 F3 COL3A1 APOH
32 ovarian hyperstimulation syndrome 30.4 SERPINC1 F5 CGB5 CGA
33 antithrombin iii deficiency 30.4 SERPINC1 MTHFR F5 F3 APOH
34 disseminated intravascular coagulation 30.4 SERPINC1 F5 F3
35 beta-thalassemia 30.3 SERPINC1 MTHFR F5 ANXA5
36 diabetes mellitus 30.3 SERPINC1 PGF PAPPA MTHFR F3 ANXA5
37 cerebral palsy 30.3 SERPINC1 MTHFR F5 CGB3 APOH ANXA5
38 vitamin k deficiency bleeding 30.2 SERPINC1 F3 AFP
39 chorioangioma 30.2 PAPPA AFP
40 factor xiii deficiency 30.2 SERPINC1 F5 F3
41 mild pre-eclampsia 30.2 SERPINC1 PGF PAPPA MIR517A
42 protein c deficiency 30.2 SERPINC1 MTHFR F5 APOH
43 von willebrand's disease 30.2 SERPINC1 F5 F3
44 factor xii deficiency 30.2 SERPINC1 F5 F3 APOH
45 factor viii deficiency 30.2 SERPINC1 F5 F3
46 transient cerebral ischemia 30.2 SERPINC1 MTHFR F3 APOH
47 thrombophlebitis 30.2 SERPINC1 MTHFR F5 F3 APOH
48 anencephaly 30.1 MTHFR CGB5 AFP
49 portal vein thrombosis 30.1 SERPINC1 MTHFR F5 F3 APOH AFP
50 neonatal anemia 30.1 PGF PAPPA

Graphical network of the top 20 diseases related to Placenta Disease:



Diseases related to Placenta Disease

Symptoms & Phenotypes for Placenta Disease

UMLS symptoms related to Placenta Disease:


morning sickness; hyperemesis gravidarum; late pregnancy bleeding; maternal fever; intrapartum fever

GenomeRNAi Phenotypes related to Placenta Disease according to GeneCards Suite gene sharing:

25 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.47 PAPPA
2 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.47 PAPPA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.47 CGB5 CGB7
4 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.47 MTHFR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.47 MTHFR
6 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.47 MTHFR
7 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.47 CGB5 CGB7
8 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.47 PAPPA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.47 MTHFR
10 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.47 MTHFR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.47 MTHFR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-95 9.47 PAPPA
13 Increased shRNA abundance GR00327-A 9.26 AFP CGB3 F5 MTHFR

MGI Mouse Phenotypes related to Placenta Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.47 AFP APOH CGA CGB3 CGB5 CGB7

Drugs & Therapeutics for Placenta Disease

Drugs for Placenta Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 236)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
2
Remifentanil Approved Phase 4 132875-61-7 60815
3
Clarithromycin Approved Phase 4 81103-11-9 84029
4
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
5
Sulfanilamide Approved Phase 4 63-74-1 5333
6
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
7
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0, 19085-09-7 4993
8
Iron Approved Phase 4 7439-89-6 29936
9
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
10
Carbetocin Approved, Investigational Phase 4 37025-55-1 16681432
11
Ferrous fumarate Approved Phase 4 141-01-5
12
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
13
Azithromycin Approved Phase 4 83905-01-5 447043
14
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
15
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 77335690 67683363
16
Cefazolin Approved Phase 4 25953-19-9 33255
17
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
18
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
19
Misoprostol Approved Phase 4 59122-46-2 5282381
20
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
21
Tranexamic acid Approved Phase 4 1197-18-8 5526
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
23
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
24
Fibrinolysin Investigational Phase 4 9004-09-5
25 Folic Acid Antagonists Phase 4
26 Folate Phase 4
27 Antimalarials Phase 4
28 Vitamin B9 Phase 4
29 Antiprotozoal Agents Phase 4
30 Antiparasitic Agents Phase 4
31 Vitamin B Complex Phase 4
32 Anesthetics Phase 4
33 Narcotics Phase 4
34 Anesthetics, Intravenous Phase 4
35 Fanasil, pyrimethamine drug combination Phase 4
36 Ferric Oxide, Saccharated Phase 4
37 Ferric Compounds Phase 4
38 Cyclooxygenase Inhibitors Phase 4
39 Antirheumatic Agents Phase 4
40 Anti-Inflammatory Agents, Non-Steroidal Phase 4
41 Analgesics, Non-Narcotic Phase 4
42 Anti-Inflammatory Agents Phase 4
43 Analgesics Phase 4
44 Anti-Infective Agents Phase 4
45 Antibiotics, Antitubercular Phase 4
46 Anti-Bacterial Agents Phase 4
47 Antiviral Agents Phase 4
48 Sofosbuvir-velpatasvir drug combination Phase 4
49 Gastrointestinal Agents Phase 4
50 Betamethasone-17,21-dipropionate Phase 4

Interventional clinical trials:

(show top 50) (show all 312)
# Name Status NCT ID Phase Drugs
1 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
2 Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy? Unknown status NCT03347513 Phase 4 triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
3 An Evaluation of Sulfadoxine-pyrimethamine Resistance and Effectiveness of IPTp in Nigeria Unknown status NCT01636895 Phase 4 Efficacy of suphladoxine/pyrimethamine as IPTp
4 An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Completed NCT03674606 Phase 4 Low dose aspirin
5 Doubling the Iron Dose VS Single Dose Iron Supplementation to Prevent Iron Deficiency Anemia (IDA) in Twin Pregnant Women: A Randomized Controlled Trial Completed NCT03836703 Phase 4 Feroglobin single daily use;Feroglobin twice daily dose
6 The Clinical Carbetocin Myocardium Trial Part 2 Completed NCT03899961 Phase 4 Oxytocin;Carbetocin
7 Low Dose Intravenous Versus Oral Iron for Iron Deficiency Anemia Starting Late in Pregnancy: A Randomized Controlled Trial Completed NCT00746551 Phase 4 Ferli-6® (Continental Pharm co., ltd.);Venofer® (Vifor AG, St. Gallen, Switzerland)
8 Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW Completed NCT00190294 Phase 4 MIFEPRISTONE 200 mg and misoprostol 400 µg
9 Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels Completed NCT01337791 Phase 4 Telbivudine treatment
10 Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus During Pregnancy (STORC) Recruiting NCT05140941 Phase 4 Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
11 Azithromycin to Improve Latency in Exam Indicated Cerclage: a Randomized Control Trial Recruiting NCT05132829 Phase 4 Azithromycin 1 gram IV;Cefazolin and indomethacin
12 Single Dose of Antenatal Corticosteroids (SNACS) Randomized Controlled Trial for Pregnancies at Risk of Preterm Delivery Not yet recruiting NCT05114096 Phase 4 Celestone + placebo;Celestone + Celestone
13 Metformin Versus Standard of Care Treatment in Pregnant Women With Prediabetes: A Randomized Trial Not yet recruiting NCT04523363 Phase 4 Metformin
14 Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial Not yet recruiting NCT05322252 Phase 4 Mifepristone;Misoprostol
15 Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk Terminated NCT02797119 Phase 4 tranexamic acid 1 g (TA1);tranexamic acid 0.5 g (TA1/2);Saline Solution (TA0)
16 Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome? Withdrawn NCT04274803 Phase 4 Intralipid, 20% Intravenous Emulsion;Conventional therapy of antiphospholipis syndrome
17 METformin in Intrahepatic Cholestasis of Pregnancy (METRIC) Study Unknown status NCT03056274 Phase 2, Phase 3 Metformin;Ursodeoxycholic Acid
18 Vitamin D During In Vitro Fertilisation (IVF) - A Prospective Randomized Trial Unknown status NCT01019785 Phase 3
19 Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes: a Randomized Controlled Trial in Pregnant Women With Hypovitaminosis D Unknown status NCT02434380 Phase 3
20 Enoxaparin for the Prevention of Placental-Mediated Complications of Pregnancy in Women With Obstetric History or Abnormal Uterine Artery Doppler at First Trimester Ultrasound and Without Thrombophilia: a Multicenter Randomized Controlled Trial Completed NCT01388322 Phase 3 Enoxaparin
21 Open Randomized Controlled Trial to Evaluate the Efficacy and Safety of Remifentanil Versus Nitrous Oxide in External Cephalic Version at Term in Singleton Pregnancy in Breech Presentation Completed NCT01735669 Phase 3 Remifentanil;Nitrous Oxide
22 Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection Completed NCT00197561 Phase 3
23 TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women. Completed NCT00967382 Phase 3 dalteparin sodium
24 A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy Completed NCT00614445 Phase 3 doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg;Placebo
25 Trial of Vitamins Among Children of HIV-infected Women Completed NCT00197730 Phase 3 Multivitamins - vitamins B complex, C and E;Placebo
26 Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia-Folic Acid Clinical Trial (FACT) Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
27 Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women? Completed NCT01273584 Phase 2, Phase 3 Metformin;Placebo
28 A Randomized Control Trial of Furosemide or Placebo With Usual Antihypertensives in the Antepartum Management of Severe Hypertension With Wide Pulse Pressure Completed NCT04615624 Phase 3 Furosemide
29 Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a Multicenter Prospective Randomized Double-blind Placebo-controlled Trial. Recruiting NCT04356326 Phase 3 Aspirin 150 mg;Placebo
30 Single Dose Antenatal Corticosteroids (SNACS) Pilot Randomized Control Trial for Women at Risk of Preterm Birth Recruiting NCT04494529 Phase 3 12 mg betamethasone + placebo;24 mg betamethasone
31 A Randomised Controlled Trial Comparing the Effect of the Faster-acting Insulin Analog - Insulin Fiasp® - Versus Insulin Novorapid® in the Treatment of Women With Type 1 or Type 2 Diabetes During Pregnancy and Lactation. The Copen-fast Trial Recruiting NCT03770767 Phase 3 Faster-acting Aspart insulin Fiasp;Control (insulin Novorapid)
32 Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial Recruiting NCT05253781 Phase 3 Low-dose aspirin
33 Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial Active, not recruiting NCT03871491 Phase 3 Azithromycin;Placebo
34 A Randomized Double Blinded Controlled Trial of Using Metformin to Prevent Preterm Birth in Twin Pregnancy Not yet recruiting NCT05412056 Phase 2, Phase 3 Metformin;Placebo oral tablet
35 Resources, Inspiration, Support and Empowerment (R.I.S.E.) for Black Pregnant Women Not yet recruiting NCT05552053 Phase 2, Phase 3
36 Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy Terminated NCT02932475 Phase 3 Metformin;Placebo
37 A Randomized Placebo-Controlled Trial of Antenatal Corticosteroid Regimens Terminated NCT00015002 Phase 3 Betamethasone
38 Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial Terminated NCT00946088 Phase 2, Phase 3 Progesterone;Polyethylene glycol&hydrogenated vegetable oil.
39 Intrahepatic Cholestasis Of Pregnancy: Clinical Impact Of Ursodeoxycholic Acid Treatment Withdrawn NCT01226823 Phase 3 Ursodeoxycholic Acid;Placebo
40 A Phase 2, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Oral Administration of Ganaxolone in Women With Postpartum Depression Completed NCT03460756 Phase 2 Ganaxolone;Placebo
41 Pilot Clinical Trial of Osteopathic Manipulative Treatment (OMT) in Pregnancy Completed NCT00298935 Phase 2
42 Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial. Completed NCT01050647 Phase 1, Phase 2 17-Hydroxyprogesterone Caproate
43 MAMAACT Intervention for Improved Reproductive Health - a Feasibility Study Completed NCT04261400 Phase 1, Phase 2
44 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Completed NCT03562897 Phase 2
45 A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression Completed NCT03228394 Phase 2 Ganaxolone;Placebo
46 A Phase 2a/2b Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in Adult Women With Intrahepatic Cholestasis of Pregnancy and Elevated Serum Bile Acid Concentrations (OHANA). Recruiting NCT04718961 Phase 2 Volixibat;Placebo
47 Trial of Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy: A Pilot Investigation Recruiting NCT05098067 Phase 2 Capsaicin Topical Cream;Metoclopramide;Ondansetron;Lactated Ringers, Intravenous
48 Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy) Recruiting NCT03152058 Phase 2 Certolizumab Pegol
49 Evaluation of the Pharmacokinetics and Pharmacodynamics of Valacyclovir in Neonates With Neonatal Herpes Simplex Virus Disease Who Have Completed Standard of Care Treatment With Acyclovir Recruiting NCT04448392 Phase 1 Valacyclovir
50 A Single Site, Interventional, Administered to Pregnant Women at High Risk for Gestational Diabetes Mellitus Recruiting NCT05265741 Phase 1

Search NIH Clinical Center for Placenta Disease

Cochrane evidence based reviews: placenta diseases

Genetic Tests for Placenta Disease

Anatomical Context for Placenta Disease

Organs/tissues related to Placenta Disease:

FMA: Placenta
MalaCards : Placenta, Heart, Brain, Lung, Endothelial, Ovary, Cervix

Publications for Placenta Disease

Articles related to Placenta Disease:

(show top 50) (show all 68)
# Title Authors PMID Year
1
Placental Therapeutic Targets and Nanodelivery Systems. 62
36228175 2022
2
Transcriptomic analysis reveals the effects of maternal selenium deficiency on placental transport, hormone synthesis, and immune response in mice. 62
36002020 2022
3
Impact of preimplantation genetic testing on obstetric and neonatal outcomes: a systematic review and meta-analysis. 62
34373103 2021
4
A Review of Biomechanics Analysis of the Umbilical-Placenta System With Regards to Diseases. 62
34475826 2021
5
Ex Vivo Dual Perfusion of the Human Placenta: Disease Simulation, Therapeutic Pharmacokinetics and Analysis of Off-Target Effects. 62
29197003 2018
6
Detergent-Insoluble Proteome Analysis Revealed Aberrantly Aggregated Proteins in Human Preeclampsia Placentas. 62
28965414 2017
7
Iliac artery balloon catheter use in abnormally invasive placenta disease management - a reply. 62
29047135 2017
8
Comparison of maternal morbidity and medical costs during pregnancy and delivery between patients with gestational diabetes and patients with pre-existing diabetes. 62
25472691 2015
9
Roles of CDX2 and EOMES in human induced trophoblast progenitor cells. 62
23313847 2013
10
Elevated hydroxyacylcarnitines in a carrier of LCHAD deficiency during acute liver disease of pregnancy - a common feature of the pregnancy complication? 53
20363656 2010
11
Full-length adiponectin attenuates insulin signaling and inhibits insulin-stimulated amino Acid transport in human primary trophoblast cells. 53
20150288 2010
12
Lack of association between unexplained elevated maternal serum alpha fetoprotein and/or human chorionic gonadotropin and the occurrence of placental thrombotic lesions. 53
20132984 2010
13
The relationship between unexplained elevated serum markers in triple test, uterine artery Doppler measurements and adverse pregnancy outcome. 53
20225773 2010
14
Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. 53
19556010 2009
15
[Thrombophilia, preeclampsia and other pregnancy complications]. 53
20034330 2009
16
Beta2-glycoprotein I and annexin A5 phospholipid interactions: artificial and cell membranes. 53
19232551 2009
17
[Angiogenic factors and their role in pathogenesis and prediction of preeclampsia]. 53
19536710 2009
18
Does thrombophilia testing help in the clinical management of patients? 53
18710381 2008
19
Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule. 53
18827058 2008
20
Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. 53
18814068 2008
21
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. 53
18175241 2008
22
The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. 53
18028481 2008
23
Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome. 53
17720945 2007
24
Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome. 53
17468256 2007
25
Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. 53
17302880 2007
26
Acute liver failure in pregnancy associated with maternal MCAD deficiency. 53
17186412 2007
27
[Genomic diagnosis of thrombophilia in women: clinical relevance]. 53
17279273 2007
28
Determination of hyperglycosylated human chorionic gonadotropin produced by malignant gestational trophoblastic neoplasias and male germ cell tumors using a lectin-based immunoassay and surface plasmon resonance. 53
17081681 2007
29
Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. 53
17919116 2007
30
Factor V Leiden, pregnancy complications and adverse outcomes. 53
16931620 2006
31
Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. 53
16855163 2006
32
[Frequency of antiphospholipid antibodies and factor V (G1691A), prothrombin (G20210A) gene polimorphism among women with pregnancy complications]. 53
17195354 2006
33
Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study. 53
16613994 2006
34
Evaluation of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase gene mutations in patients with severe pregnancy complications in northern Finland. 53
16514238 2006
35
Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. 53
16086443 2005
36
[Impact of inherited thrombophilia on the development of some pregnancy complications]. 53
16313049 2005
37
Lack of correlation between fatty acid oxidation disorders and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome? 53
15858960 2005
38
Elevated second-trimester free beta-hCG as an isolated finding and pregnancy outcomes. 53
15539871 2004
39
Associations between maternal methylenetetrahydrofolate reductase polymorphisms and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. 53
15210385 2004
40
First trimester screening for trisomy 21; Do the parameters used detect more pathologies than just Down syndrome? 53
15099868 2004
41
Maternal serum free beta-hCG levels in uncomplicated pregnancies at the 10th-15th week of gestation and the development of obstetric complications. 53
15018435 2004
42
Pronto ThromboRisk--a novel primer-extension ELISA based assay for the detection of mutations associated with increased risk for thrombophilia. 53
15356875 2004
43
Haemostatic changes in pregnancy. 53
15507271 2004
44
Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. 53
14663836 2003
45
Maternal midtrimester free beta-HCG and AFP serum levels in spontaneous singleton pregnancies complicated by gestational diabetes mellitus, pregnancy-induced hypertension or obstetric cholestasis. 53
14691989 2003
46
Human chorionic gonadotropin and vascular endothelial growth factor in normal and complicated pregnancies. 53
14672476 2003
47
Characterization of a pseudogene for murine methylenetetrahydrofolate reductase. 53
14577615 2003
48
Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. 53
14526312 2003
49
Autoimmune disease as a cause of reproductive failure. 53
12848445 2003
50
Procoagulant and anticoagulant mechanisms in human placenta. 53
12709921 2003

Variations for Placenta Disease

Expression for Placenta Disease

Search GEO for disease gene expression data for Placenta Disease.

GO Terms for Placenta Disease

Cellular components related to Placenta Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.2 SERPINC1 PGF PAPPA F5 F3 COL3A1
2 extracellular space GO:0005615 10.02 AFP APOH CGA CGB3 CGB5 CGB7
3 pituitary gonadotropin complex GO:0061696 9.02 CGB5 CGB3 CGA

Biological processes related to Placenta Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.76 SERPINC1 F5 F3 ANXA5
2 hormone-mediated signaling pathway GO:0009755 9.65 CGB5 CGB3 CGA
3 female gamete generation GO:0007292 9.35 CGB7 CGB5 CGB3
4 regulation of blood coagulation GO:0030193 9.32 SERPINC1 APOH
5 hemostasis GO:0007599 8.92 SERPINC1 F5 F3 ANXA5

Molecular functions related to Placenta Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.17 CGB7 CGB5 CGB3 CGA

Sources for Placenta Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....